 Palivizumab is used to reduce the risk of respiratory syncytial virus in children at increased risk of severe disease.The American Academy of Pediatrics has published guidelines for the use of palivizumab.The most recent updates to these recommendations are based on new information regarding RSV seasonality, palivizumab pharmacokinetics, the incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effect of prophylaxis on wheezing, and palivizumab-resistant RSV isolates.